Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: An in vitro pharmacodynamic simulation

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 6, 2006, Pages 1128-1133

  Sevillano, David ^a   Alou, Luis ^a   Aguilar, Lorenzo ^a   Echevarría, Olatz ^a   Giménez, María José ^a   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Antipneumococcal bactericidal activity; In vitro models; Resistance genotypes

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; ERMTR PROTEIN, BACTERIA; MEFA PROTEIN, STREPTOCOCCUS; MEMBRANE PROTEIN; METHYLTRANSFERASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BODY FLUID; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EPITHELIUM; ERADICATION THERAPY; GENOTYPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PREDICTION; SERUM; STREPTOCOCCUS PNEUMONIAE; BACTERIAL COUNT; BIOLOGICAL MODEL; BLOOD; DRUG EFFECT; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; BACTERIAL PROTEINS; BODY FLUIDS; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DRUG RESISTANCE, BACTERIAL; EPITHELIUM; INJECTIONS, INTRAVENOUS; MEMBRANE PROTEINS; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STREPTOCOCCUS PNEUMONIAE;

EID: 33749185301     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl140     Document Type: Article

References (19)

1. Amsden GW. Erythromycin, clarithromycin, and azithromycin: Are the differences real? Clin Ther 1996; 18: 56-72.
2. Glaude RP, Bright CM, Isaacson RE et al. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277-82.
3. Luke DR, Foulds G, Cohen SF et al. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996; 40: 2577-81.
4. Chiu LM, Menhinick AM, Johnson PW et al. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J Antimicrob Chemother 2002; 50: 1075-9.
5. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmcokinet 1993; 25: 370-4.
6. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother 1999; 33: 218-28.
7. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003; 47: 2450-7.
8. Firsov AA, Zinner SH, Vostrov SN et al. Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. J Antimicrob Chemother 2002; 49: 113-9.
9. Zhanel GG, DeCorby M, Noreddin A et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 2003: 52: 83-8.
10. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement. CLSI Docurnent M100-S15. CLSI, Wayne, PA, USA, 2005.
11. Hoban DJ, Wierzbowski AK, Nichol K et al. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: Prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother 2001; 45: 2147-50.
12. Seviliano D, Calvo A, Giménez MJ et al. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 2004; 54: 1148-51.
13. NDA 50-733/S-005. Zithromax. http://www.fda.gov/cder/foi/label/2001/ 50733s5lbl.pdf (23 January 2006, date last accessed).
14. Danesi R, Lupetti A, Barbara C et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 2003; 51: 939-45.
15. Pérez-Trallero E. García-de-la-Fuente C, García-Rey C et al. Geographical and ecological analysis of resistance, coresistance and coupled resistance to antimicrobials in and between respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
16. Brown SD, Farrell DJ, Morrissey I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J Clin Microbiol 2004; 42: 4980-7.
17. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14: 165-72.
18. Lonks JR, Garau J, Gómez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64.
19. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.